{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:31Z","timestamp":1793262931828,"version":"4.5.0"},"reference-count":70,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"\n \n \n ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the<\/jats:italic>\n \n ASCO Guidelines Methodology Manual<\/jats:italic>\n <\/jats:ext-link>\n . ASCO Guidelines follow the<\/jats:italic>\n \n ASCO Conflict of Interest Policy for Clinical Practice Guidelines<\/jats:italic>\n <\/jats:ext-link>\n .\n <\/jats:p>\n \n \n Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in\n Appendix 1<\/jats:xref>\n and\n 2<\/jats:xref>\n (online only) for more.\n <\/jats:italic>\n <\/jats:p>\n <\/jats:sec>\n \n PURPOSE<\/jats:title>\n Extravasation is an uncommon but high-risk adverse event that occurs when an agent with the potential to cause tissue damage leaks out of the intended administration space into the surrounding area. This guideline presents evidence-based side effect management recommendations to support interprofessional teams in decision making to minimize severity or progression of extravasation injury from antineoplastic treatment in individuals with cancer.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n The Oncology Nursing Society and American Society of Clinical Oncology appointed health care professionals and patient representative members to a panel for guideline development focused on antineoplastic vesicants and irritants with vesicant properties. The panel applied GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology and followed the National Academies of Sciences, Engineering, and Medicine criteria for trustworthy guidelines. A systematic review of studies examining outcomes of antineoplastic agent extravasation in adults informed the guideline. The panel assessed the certainty of the evidence using the GRADE approach.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The panel agreed on recommendations related to the use of antidotes for antineoplastic vesicants and irritants with vesicant properties, thermal compress application and duration, and early surgical referral or escalation to specialty care for central venous access device extravasation.<\/jats:p>\n <\/jats:sec>\n \n RECOMMENDATIONS<\/jats:title>\n This guideline summarizes evidence-based interventions for the management of extravasation of antineoplastic vesicants or irritants with vesicant properties to guide clinical care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/op-25-00579","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:59:06Z","timestamp":1758225546000},"page":"924-938","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["ONS\/ASCO Guideline on the Management of Antineoplastic Extravasation"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6568","authenticated-orcid":true,"given":"Tanya","family":"Thomas","sequence":"first","affiliation":[{"name":"UVA Health, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3272-2054","authenticated-orcid":true,"given":"Caroline","family":"Clark","sequence":"additional","affiliation":[{"name":"Oncology Nursing Society, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2102-5349","authenticated-orcid":true,"given":"Chelsea","family":"Backler","sequence":"additional","affiliation":[{"name":"Oncology Nursing Society, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-7903","authenticated-orcid":true,"given":"Kari","family":"Bohlke","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena","family":"Centofanti","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna C.","family":"Jotwani","sequence":"additional","affiliation":[{"name":"Department of Medicine in the Section of Hematology and Oncology at Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane G.","family":"Cope","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists and Research Institute, Fort Myers, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri A.","family":"Dalton","sequence":"additional","affiliation":[{"name":"Nursing Research and Evidence-Based Practice Department at Duke University Health System, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine G.","family":"Gochett","sequence":"additional","affiliation":[{"name":"Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Henney","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"King","sequence":"additional","affiliation":[{"name":"University of Colorado Hospital, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-9505","authenticated-orcid":true,"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-2976","authenticated-orcid":true,"given":"Hannah Dzimitrowicz","family":"McManus","sequence":"additional","affiliation":[{"name":"School of Medicine in the Department of Medicine, Medical Oncology, at Duke University, Durham, NC"},{"name":"Center for Prostate and Urologic Cancers at the Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5435-3736","authenticated-orcid":true,"given":"Holly M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Breast Cancer Coalition, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri A.","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Oncology Nursing Society, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"DiValerio Gibbs","sequence":"additional","affiliation":[{"name":"Department of Undergraduate Studies in the Cizik School of Nursing at the University of Texas Health Science Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences in the School of Medicine at Case Western Reserve University, Cleveland, OH"},{"name":"Evidence Foundation, Cleveland, OH"},{"name":"Department of Health Research Methods, Evidence, and Impact in the Faculty of Health Sciences at McMaster University in Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","unstructured":"National Cancer Institute: Chemotherapy to treat cancer 2022. https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/chemotherapy"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.3352\/jeehp.2020.17.21"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-002152"},{"key":"e_1_3_9_5_2","first-page":"438","article-title":"Chemotherapy extravasation: Establishing a national benchmark for incidence among cancer centers","volume":"21","author":"Jackson-Rose J","year":"2017","unstructured":"Jackson-Rose J, Del Monte J, Groman A, et al: Chemotherapy extravasation: Establishing a national benchmark for incidence among cancer centers. Clin J Oncol Nurs 21:438-445, 2017","journal-title":"Clin J Oncol Nurs"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v7.i1.87"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000411"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.37689\/acta-ape\/2020AO0075"},{"key":"e_1_3_9_9_2","volume-title":"Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice","author":"Olsen MA","year":"2023","unstructured":"Olsen MA, LeFebvre K, Walker SL, et al: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (ed 2), Oncology Nursing Society, Pittsburgh, PA, 2023","edition":"2"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132308"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.5301\/jva.5000316"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000486"},{"key":"e_1_3_9_13_2","first-page":"28","volume-title":"Antineoplastic Extravasation Prevention, Management","author":"Billias C","year":"2021","unstructured":"Billias C, Menon M: Antineoplastic Extravasation Prevention, Management. Pharm Times 3:28-30, 2021"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh214"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00816"},{"key":"e_1_3_9_16_2","first-page":"4789","article-title":"Knowledge of the nursing team on the prevention and management of extravasation of chemotherapy drugs","volume":"11","author":"Gozzo TO","year":"2017","unstructured":"Gozzo TO, Santos LAC, Cruz LAP: Knowledge of the nursing team on the prevention and management of extravasation of chemotherapy drugs. J Nurs UFPE 11:4789-4797, 2017","journal-title":"J Nurs UFPE"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231167873"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525525"},{"key":"e_1_3_9_19_2","first-page":"403","article-title":"Management of extravasation of antineoplastic agents in patients undergoing treatment for cancer: A systematic review and meta-analysis","volume":"52","author":"Gibbs KD","year":"2025","unstructured":"Gibbs KD, Pasumarthi T, Watson M, et al: Management of extravasation of antineoplastic agents in patients undergoing treatment for cancer: A systematic review and meta-analysis. Oncol Nurs Forum 52:403-412, 2025","journal-title":"Oncol Nurs Forum"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.06.004"},{"key":"e_1_3_9_21_2","volume-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines: Clinical practice guidelines we can trust","author":"Institute of Medicine (US)","year":"2011","unstructured":"Institute of Medicine (US): Committee on Standards for Developing Trustworthy Clinical Practice Guidelines: Clinical practice guidelines we can trust, in Graham R, Mancher M, Miller Wolman D, et al (eds): Washington DC, National Academies Press, 2011. https:\/\/nap.edu\/catalog\/13058\/clinical-practice-guidelines-we-can-trust"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131237"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"e_1_3_9_24_2","first-page":"771","article-title":"The management of cytotoxic chemotherapy extravasation: A systematic review of the literature to evaluate the evidence underpinning contemporary practice","volume":"24","author":"Harrold K","year":"2015","unstructured":"Harrold K, Gould D, Drey N: The management of cytotoxic chemotherapy extravasation: A systematic review of the literature to evaluate the evidence underpinning contemporary practice. Eur J Cancer Care (Engl) 24:771-800, 2015","journal-title":"Eur J Cancer Care (Engl)"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_9_26_2","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al: Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Evid Synth 18:2127-2133, 2020","journal-title":"JBI Evid Synth"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_3_9_29_2","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime 2025. gradepro.org"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl413"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2851"},{"key":"e_1_3_9_32_2","first-page":"169","article-title":"The efficacy of saline washout technique in the management of exfoliant and vesicant chemotherapy extravasation: A historical case series report","volume":"22","author":"Harrold K","year":"2013","unstructured":"Harrold K, Gould D, Drey N: The efficacy of saline washout technique in the management of exfoliant and vesicant chemotherapy extravasation: A historical case series report. Eur J Cancer Care (Engl) 22:169-178, 2013","journal-title":"Eur J Cancer Care (Engl)"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1188\/15.CJON.E25-E30"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20248"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.11.1732"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2535-2"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2010.04.040"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1382-2"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-200206000-00011"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12103"},{"key":"e_1_3_9_41_2","first-page":"32","article-title":"New formulation of bendamustine associated with phlebitis: Report of 2 unique patient cases","volume":"9","author":"Ajewole V","year":"2019","unstructured":"Ajewole V, Edmondson L, McLean E, et al: New formulation of bendamustine associated with phlebitis: Report of 2 unique patient cases. J Hematol Oncol Pharm 9:32-35, 2019","journal-title":"J Hematol Oncol Pharm"},{"key":"e_1_3_9_42_2","unstructured":"Akorn Inc: Hydase\u2122 Bovine: Highlights of prescribing information 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021716s003lbl.pdf"},{"key":"e_1_3_9_43_2","unstructured":"American Society of Health-System Pharmacists: Antidote reversal agents and rescue agents critical inventory list. https:\/\/www.ashp.org\/-\/media\/assets\/pharmacy-practice\/resource-centers\/patient-safety\/doc\/Antidote-Reversal-Agents-and-Rescue-Agents-Critical-Inventory-List.pdf"},{"key":"e_1_3_9_44_2","unstructured":"Apricus Pharma: Totect\u00ae kit: Highlights of prescribing information 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022025s013lbl.pdf"},{"key":"e_1_3_9_45_2","doi-asserted-by":"publisher","DOI":"10.4081\/pr.2012.e28"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.36518\/2689-0216.1451"},{"key":"e_1_3_9_47_2","volume-title":"Dexrazoxane, StatPearls","author":"Eneh C","year":"2023","unstructured":"Eneh C, Lekkala MR: Dexrazoxane, StatPearls. StatPearls Publishing, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560559\/"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001743"},{"key":"e_1_3_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.08.005"},{"key":"e_1_3_9_50_2","volume-title":"Health Promotion, Inequalities and Young People\u2019s Health: A Systematic Review of Research (Report No. 1611)","author":"Oliver S","year":"2008","unstructured":"Oliver S, Kavanagh J, Caird J, et al: Health Promotion, Inequalities and Young People\u2019s Health: A Systematic Review of Research (Report No. 1611). EPPI-Centre, Social Science Research Unit, Institute of Education, University of London, London, United Kingdom, 2008"},{"key":"e_1_3_9_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000637-200210000-00006"},{"key":"e_1_3_9_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198503000-00017"},{"key":"e_1_3_9_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt186"},{"key":"e_1_3_9_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds294"},{"key":"e_1_3_9_55_2","volume-title":"Access Device Guidelines: Recommendations for Nursing Practice and Education","author":"Backler C","year":"2023","unstructured":"Backler C, Kirmse JM: Access Device Guidelines: Recommendations for Nursing Practice and Education (ed 4). Oncology Nursing Society, Pittsburgh, PA, 2023","edition":"4"},{"key":"e_1_3_9_56_2","first-page":"297","article-title":"Antineoplastic therapy administration safety standards for adult and pediatric oncology: ASCO-ONS standards","volume":"51","author":"Siegel RD","year":"2024","unstructured":"Siegel RD, LeFebvre KB, Temin S, et al: Antineoplastic therapy administration safety standards for adult and pediatric oncology: ASCO-ONS standards. Oncol Nurs Forum 51:297-320, 2024","journal-title":"Oncol Nurs Forum"},{"key":"e_1_3_9_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000532"},{"key":"e_1_3_9_58_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_3_9_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0000000000000392"},{"key":"e_1_3_9_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231185505"},{"key":"e_1_3_9_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16502"},{"key":"e_1_3_9_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004323"},{"key":"e_1_3_9_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004089"},{"key":"e_1_3_9_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13148"},{"key":"e_1_3_9_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101525"},{"key":"e_1_3_9_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2456092"},{"key":"e_1_3_9_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.08.014"},{"key":"e_1_3_9_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6473"},{"key":"e_1_3_9_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00542"},{"key":"e_1_3_9_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2311"},{"key":"e_1_3_9_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:26Z","timestamp":1781647226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/OP-25-00579"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00579","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1200\/GDL.25.0918","asserted-by":"subject"}]},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}